<DOC>
	<DOCNO>NCT00811447</DOCNO>
	<brief_summary>Primary objective : To detect statistically significant increase time progression ( TTP ) disease test group ( Taxotere® [ Docetaxel ] combine cisplatin 5-fluorouracil [ TCF ] ) relative control group ( Cisplatin combine 5-fluorouracil [ CF ] ) Secondary objective : - To detect statistically significant increase overall survival ( OS ) test group relative control group . - To compare response rate ( RR ) , time treatment failure ( TTF ) , duration response , safety profile , quality life ( QOL ) , disease-related symptom .</brief_summary>
	<brief_title>Taxotere New Indication - Gastric Cancer Treatment Registration Trial</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Gastric adenocarcinoma include adenocarcinoma esophagogastric junction , histologically proven . Measurable and/or evaluable metastatic disease ; single metastatic lesion manifestation disease , cytology histology mandatory . Locally recurrent disease accept provide least one measurable lesion . Performance status Karnofsky index &gt; 70 % Life expectancy 3 month Adequate haematological parameter ( Hb≥9g/dl , ANC≥2.0× 109/L , platelet ≥ 100× 109/L ) Creatinine ≤ 1.25 UNL , serum magnesium within normal value Total bilirubin ≤ 1 UNL , AST ALT ≤ 2.5 UNL , alkaline phosphatase ≤ 5 UNL No prior palliative chemotherapy , previous adjuvant chemotherapy allow 12 month elapse end adjuvant therapy first relapse . At least 6 week prior radiotherapy 3 week surgery Complete initial workup within two week prior first infusion clinical evaluation biological workup . Abdominal CT scan chest Xrays mandatory . Pregnant lactating woman Patients reproductive potential implementing adequate contraceptive measure Other tumor type adenocarcinoma Any prior palliative chemotherapy . Prior adjuvant chemotherapy first relapse within 12 month end adjuvant Prior treatment taxanes . Prior CDDP adjuvant chemotherapy cumulative dose &gt; 300mg/m² Previous current malignancy gastric carcinoma , exception adequately treat situ carcinoma cervix uteri non melanoma skin cancer Patients know brain leptomeningeal metastases Symptomatic peripheral neuropathy ≥ grade 2 NCICCTG criterion Other serious illness medical condition : unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry history significant neurologic psychiatric disorder include dementia seizure active uncontrolled infection active disseminate intravascular coagulation serious underlie medical condition could impair ability patient participate study Concurrent treatment corticosteroid except use prophylactic medication regimen , treatment acute hypersensitivity reaction unless chronic treatment low dose Definite contraindication use corticosteroid Hypercalcemia control bisphosphonates 12mg/100ml Liver impairment AST ALT 1.5UNL associate alkaline phosphatase 2.5UNL Concurrent within 4 week period administration experimental drug Concurrent treatment anticancer therapy The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>